Bulletin
Investor Alert

May 25, 2020, 9:16 a.m. EDT

Stocks Trading Above 52 Week Low and Below 52 Week High: $IOVA $CRBP $FATE

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Iovance Biotherapeutics Inc. (IOVA)
  • X
    Corbus Pharmaceuticals Holdings Inc. (CRBP)
  • X
    Fate Therapeutics Inc. (FATE)

or Cancel Already have a watchlist? Log In

May 25, 2020 (The Market Signal via Comtex) -- Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they own. If you are a shareholder or looking for stocks to buy /zigman2/quotes/206632254/composite IOVA -2.36% , /zigman2/quotes/201549545/composite CRBP +3.93% or /zigman2/quotes/209623007/composite FATE +6.41% then we strongly urge you to join our community by signing up with the link below and getting a completely free research report on each company today.

http://www.sectorreports.com.au/Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Iovance Biotherapeutics, Inc. Spends $57.0 Million for Q1 2020 in Internal R&D

https://www.sectorreports.com.au/landing-page/?symbol=IOVA

(Click link above or copy, paste and hit enter in your browser for your report)

Iovance Biotherapeutics, Inc. /zigman2/quotes/206632254/composite IOVA -2.36% is 155.45% above its 52-Week Low, and 5.13% above its 52-Week high, the stock looks bullish. Late-stage Biotechnology Company specializing in creating novel T cell-based cancer immunotherapies reported financial results for its first quarter of the year for the period ending March 31, 2020. Iovance Biotherapeutics reported a net loss for Q1 2020 at $69.6 million, or $0.55 per share as compared with a net loss of $37.0 million, or $0.30 per share, for Q1 2019.

Research and development expenses came out at $57.0 million for Q1 2020, indicating an increase of $26.1 million as compared to $30.9 million for Q1 2019. This surge is attributed to an increase in the license costs to the IOV-3001 IL-2 analog sourcing from Novartis. Other factors that contributed to this increase include growth in in-company R&D, along with more number of manufacturing activities.

At the end of quarter reported, Iovance Biotherapeutics had cash, cash equivalents, short-term investments, and restricted cash of $251.2 million as against $312.5 million on December 31, 2019.

Corbus Announces Two Abstracts Publication at European League against Rheumatism Congress

https://www.sectorreports.com.au/landing-page/?symbol=CRBP

(Click link above or copy, paste and hit enter in your browser for your report)

Corbus Pharmaceuticals Holdings Inc /zigman2/quotes/201549545/composite CRBP +3.93% is 144.98% above its 52-Week Low, and 5.08% above its 52-Week high. This is a well-placed stock and appears bullish. Clinical-stage drug Development Company that pioneers in medicines that focus on endocannabinoid system, last week, announced that two of its abstracts are published and will take place in European League Against Rheumatism (EULAR) 2020 E-Congress. These abstracts will be held at the EULAR 2020 Congress from June 3-6, 2020.

These abstracts are published in e-Abstract Book, which serves as Annals of Rheumatic Diseases ARD supplements.

These abstracts are titled Lenabasum, a CB2 agonist, inhibits inflammasome activation (Programme Number AB0152), and Baseline European Patient Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum (Programme Number AB0568).

Fate Therapeutics Given FDA Nod for First CRISPR-Edited, iPSC -Derived Cell Therapy Drug

https://www.sectorreports.com.au/landing-page/?symbol=FATE

(Click link above or copy, paste and hit enter in your browser for your report)

/zigman2/quotes/206632254/composite
US : U.S.: Nasdaq
$ 28.53
-0.69 -2.36%
Volume: 780,752
Aug. 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.28 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/201549545/composite
US : U.S.: Nasdaq
$ 6.87
+0.26 +3.93%
Volume: 1.65M
Aug. 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$540.12 million
Rev. per Employee
$62,627
loading...
/zigman2/quotes/209623007/composite
US : U.S.: Nasdaq
$ 36.00
+2.17 +6.41%
Volume: 786,680
Aug. 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.94 billion
Rev. per Employee
$45,577
loading...
/zigman2/quotes/206632254/composite
US : U.S.: Nasdaq
$ 28.53
-0.69 -2.36%
Volume: 780,752
Aug. 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.28 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/201549545/composite
US : U.S.: Nasdaq
$ 6.87
+0.26 +3.93%
Volume: 1.65M
Aug. 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$540.12 million
Rev. per Employee
$62,627
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.